Cabazitaxel
A taxane chemotherapy agent used to treat metastatic castration-resistant prostate cancer in patients who have previously received docetaxel-based treatment. It stabilizes microtubules to prevent cancer cells from dividing and is notable for activity in tumors that have become resistant to docetaxel. Severe neutropenia is its most serious side effect.
Moleküler Ağırlık
835,9000 g/mol
LogP
2,70
TPSA
202,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
Molecular Formula
C45H57NO14
HBD / HBA
3 / 14
Döndürülebilir Bağlar
15
Ağır Atomlar
60
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A taxane chemotherapy agent used to treat metastatic castration-resistant prostate cancer in patients who have previously received docetaxel-based treatment. It stabilizes microtubules to prevent cancer cells from dividing and is notable for activity in tumors that have become resistant to docetaxel. Severe neutropenia is its most serious side effect.
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Yes, Cabazitaxel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201748. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9854073. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabazitaxel"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabazitaxel/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabazitaxel/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabazitaxel/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabazitaxel"></drugfyi-drug>